肿瘤组织microRNA-21高表达增加淋巴结转移的荟萃分析

doi:10.16139/j.1007-9610.2018.03.016

摘要/Abstract

摘要： 目的: 分析不同肿瘤组织中microRNA-21（miR-21）的异常表达及其与淋巴结转移的相关性。方法: 检索PubMed、Web of Science 、EMbase、CBM数据库,截至2017年10月。采用随机效应模型,计算肿瘤组织miR-21表达高、低两组淋巴结转移的OR、95%CI。同时,本研究也运用异质性检验、敏感性分析和出版偏移等统计学分析。结果: 最终纳入16篇文献共1 492例。miR-21表达水平较高组（OR=2.01, 95%CI=1.36~2.97, P<0.001）明显增加淋巴结转移。亚组分析结果表明,miR-21高表达组在消化系统肿瘤（OR=2.22,95%CI=1.49~3.30）,膀胱和宫颈癌（OR=5.48,95%CI=1.84~16.30）中明显增加淋巴结转移风险,其中也发现病人样本数<60例,OR=2.39, 95%CI=1.44~3.98, P<0.001;≥60例,OR=1.78, 95%CI=1.04~3.05, P=0.036。乳腺癌、喉和肺癌的miR-21表达,未发现与淋巴结转移的关系。结论: 本研究发现,肿瘤组织miR-21高表达组明显增加淋巴结转移的风险。亚组分析结果表明,miR-21在消化系统肿瘤以及膀胱和宫颈癌中,可作为淋巴结转移的标志物。

关键词: miR-21, 肿瘤组织, 淋巴结转移, 荟萃分析

Abstract: Objective: To explore the association of abnormal microRNA-21(miR-21) expression in cancer tissues with lymph node metastasis. Methods: We searched PubMed, Web of Science, EMbase and CBM databases until October 2017 to retrieve the relevant articles on miR-21 expression in cancer tissues and lymph node metastasis. Random-effects model was adopted to calculate OR and 95%CI of the risk of lymph node metastasis in the group of miR-21 higher expression and the group of lower expression. The statistical analyses including heterogeneity tests, sensitivity analysis and publication bias were performed in this meta-analysis. Results: A total of 16 studies involving 1 492 cases revealed that higher expression of miR-21 in cancers was found to be associated with lymph node metastasis (pooled OR=2.01, 95%CI=1.36-2.97, P<0.001). According to subgroup analysis, it was indicated that miR-21 higher expression was significantly related to the risk of lymph node metastasis for cancer in digestive system (OR=2.22, 95%CI=1.49-3.30), bladder cancer and cervical cancer (OR=5.48, 95%CI=1.84-16.30), <60 cases (OR=2.39, 95%CI=1.44-3.98), ≥60 cases (OR=1.78, 95%CI=1.04-3.05), respectively. Conclusions: It is shown in this meta-analysis that the risk of lymph node metastasis in patients was associated with higher miR-21 expression. The subgroup analysis indicated that miR-21 expression may serve as a mole-cular marker for lymph node metastasis in digestive system tumors and bladder cancer and cervical cancer.

Key words: miR-21, Cancer tissue, Lymph node metastasis, Meta-analysis

中图分类号:

R73-37

洪勇智, 刘晓阳, 王晋, 赵亮, 赵鹏. 肿瘤组织microRNA-21高表达增加淋巴结转移的荟萃分析[J]. 外科理论与实践, 2018, 23(03): 263-270.

HONG Yongzhi, LIU Xiaoyang, WANG Jin, ZHAO Liang, ZHAO Peng. MicroRNA-21 higher expression in cancer tissues elevates lymph node metastasis: a meta-analysis[J]. Journal of Surgery Concepts & Practice, 2018, 23(03): 263-270.

参考文献

[1] Bartel DP.MicroRNAs: target recognition and regulatory functions[J]. Cell,2009,136(2):215-233.
[2] Brennecke J, Hipfner DR, Stark A, et al.Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila[J]. Cell,2003,113(1):25-36.
[3] Reinhart BJ, Slack FJ, Basson M, et al.The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature,2000,403(6772):901-906.
[4] Pillai RS.MicroRNA function: multiple mechanisms for a tiny RNA?[J]. RNA,2005,11(12):1753-1761.
[5] Iorio MV, Croce CM. microRNA involvement in human cancer[J]. Carcinogenesis,2012,33(6):1126-1133.
[6] Jay C, Nemunaitis J, Chen P, et al.miRNA profiling for diagnosis and prognosis of human cancer[J]. DNA Cell Biol,2007,26(5):293-300.
[7] Yu SL, Chen HY, Yang PC, et al.Unique MicroRNA signature and clinical outcome of cancers[J]. DNA Cell Biol,2007,26(5):283-292.
[8] Esquela-Kerscher A, Slack FJ.Oncomirs microRNAs with a role in cancer[J]. Nat Rev Cancer,2006,6(4):259-269.
[9] De Yebenes VG, Ramiro AR.MicroRNA activity in B lymphocytes[J]. Methods Mol Biol,2010,667:177-192.
[10] Lee EJ, Gusev Y, Jiang J, et al.Expression profiling ide-ntifies microRNA signature in pancreatic cancer[J]. Int J Cancer,2007,120(5):1046-1054.
[11] Feber A, Xi L, Luketich JD, et al.MicroRNA expression profiles of esophageal cancer[J]. J Thorac Cardiovasc Surg,2008,135(2):255-260.
[12] Yanaihara N, Caplen N, Bowman E, et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis[J]. Cancer Cell,2006,9(3):189-198.
[13] Schetter AJ, Leung SY, Sohn JJ, et al.MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J]. JAMA,2008, 299(4):425-436.
[14] Chan JA, Krichevsky AM, Kosik KS.MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells[J]. Cancer Res,2005,65(14):6029-6033.
[15] Qi L, Bart J, Tan LP, et al.Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma[J]. BMC Cancer,2009,9:163.
[16] Ali S, Almhanna K, Chen W, et al.Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer[J]. Am J Transl Res,2010,3(1):28-47.
[17] Yan LX, Huang XF, Shao Q, et al.MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis[J]. RNA,2008,14(11):2348-2360.
[18] Gao W, Shen H, Liu L, et al.MiR-21 overexpression in human primary squamous cell lung carcinoma is associa-ted with poor patient prognosis[J]. J Cancer Res Clin Oncol,2011,137(4):557-566.
[19] Huang Q, Liu L, Liu CH, et al.MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis[J]. Asian Pac J Cancer Prev,2013,14(2):829-834.
[20] Bundred NJ.Prognostic and predictive factors in breast cancer[J]. Cancer Treat Rev,2001,27(3):137-142.
[21] Hu A, Huang JJ, Xu WH, et al.miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival[J]. Am J Transl Res,2014,6(5):604-613.
[22] Caponi S, Funel N, Frampton AE, et al.The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms[J]. Ann Oncol,2013,24(3):734-741.
[23] Dong G, Liang X, Wang D, et al.High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation[J]. Med Oncol,2014,31(7):57.
[24] Tian L, Shan W, Zhang Y, et al.Up-regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer[J]. Pathol Oncol Res,2016,22(1):161-167.
[25] Giovannetti E, Funel N, Peters GJ, et al.MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity[J]. Cancer Res,2010, 70(11):4528-4538.
[26] Chen TH, Chang SW, Huang CC, et al.The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer[J]. Colorectal Dis,2013,15(11):1367-1374.
[27] Han Y, Xu GX, Lu H, et al.Dysregulation of miRNA-21 and their potential as biomarkers for the diagnosis of cervical cancer[J]. Int J Clin Exp Pathol,2015,8(6):7131-7139.
[28] Motoyama K, Inoue H, Mimori K, et al.Clinicalpatholo-gical and prognostic significance of PDCD4 and micro RNA-21 in human gastric cancer[J]. Int J Oncol,2010,36(5):1089-1095.
[29] Capodanno A, Boldrini L, Proietti A, et al.Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features[J]. Int J Oncol,2013,43(3):765-774.
[30] Yan LX, Liu YH, Xiang JW, et al.PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer[J]. Int J Oncol,2016,48(2):471-484.
[31] Lee JA, Lee HY, Lee ES, et al.Prognostic implicatiopns of microRNA-21 overexpression in invasive ductal carcinomas of the breast[J]. J Breast Cancer,2011,14(4):269-275.
[32] Nagao Y, Hisaoka M, Matsuyama A, et al.Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma[J]. Mod Pathol,2012,25(1):112-121.
[33] Zhang HH, Qi F, Cao YH, et al.Expression and clinical significance of microRNA-21, maspin and vascular endothelial growth factor-C in bladder cancer[J]. Oncol Lett,2015,10(4):2610-2616.
[34] Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell,2004,116(2):281-297.
[35] Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for[J]. Oncogene,2006,25(46):6176-6187.
[36] Kloosterman WP, Plasterk RH.The diverse functions of microRNAs in animal development and disease[J]. Dev Cell,2006,11(4):441-450.
[37] Song B, Wang C, Liu J, et al.MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression[J]. J Exp Clin Cancer Res,2010,29:29.
[38] Meng F, Henson R, Lang M, et al.Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines[J]. Gastroenterology,2006,130(7):2113-2129.
[39] Frankel LB, Christoffersen NR, Jacobsen A, et al.Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells[J]. J Biol Chem,2008,283(2):1026-1033.
[40] Blower PE, Chung JH, Verducci JS, et al.MicroRNAs modulate the chemosensitivity of tumor cells[J]. Mol Cancer Ther,2008,7(1):1-9.
[41] Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA[J]. J Cell Mol Med,2009,13(1):39-53.
[42] Yang HS, Matthews CP, Clair T, et al.Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion[J]. Mol Cell Biol,2006,26(4):1297-1306.
[43] Asangani IA, Rasheed SA, Nikolova DA, et al.MicroRNA-21(miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer[J]. Oncogene,2008,27(15):2128-2136.
[44] Chen Y, Liu W, Chao T, et al.MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G[J]. Cancer Lett,2008,272(2):197-205.
[45] Ahonen M, Poukkula M, Baker AH, et al.Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors[J]. Oncogene,2003,22(14):2121-2134.
[46] Demei M, Xiangxin L, Yongping X, et al.Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer[J]. J Int Med Res,2013,41(5):1541-1549.
[47] Zhang Y, Meng X, Zeng H, et al.Serum vascular endothelial growth factor-C levels: A possible diagnostic marker for lymph node metastasis in patients with primary non-small cell lung cancer[J]. Oncol Lett,2013,6(2):545-549.
[48] Zhang BG, Li JF, Yu BQ, et al.microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN[J]. Oncol Rep,2012,27(4):1019-1026.
[49] Li P, Mao WM, Zheng ZG, et al.Down-regulation of PTEN expression modulated by dysregulated miR-21 contributes to the progression of esophageal cancer[J]. Dig Dis Sci,2013,58(12):3483-3493.
[50] Xiong B, Cheng Y, Ma L, et al.MiR-21 regulates biolo-gical behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells[J]. Inter J Oncol,2013,42(1):219-228.
[51] Vogt PK, Gymnopoulos M, Hart JR.PI 3-kinase and cancer: changing accents[J]. Curr Opin Genet Dev,2009, 19(1):12-17.
[52] Oh J, Takahashi R, Kondo S, et al.The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis[J]. Cell,2001, 107(6):789-800.
[53] Wang N, Zhang CQ, He JH, et al.MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma[J]. Dig Dis Sci,2013,58(7):1863-1870.
[54] Zhang L, Zhan X, Yan D, et al.Circulating microRNA-21 is involved in lymph node metastasis in cervical cancer by targeting RASA1[J]. Inter J Gynecol Cancer,2016, 26(5):810-816.
[55] Li T, Li RS, Li YH, et al.miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer[J]. J Urol,2012,187(4):1466-1472.
[56] Chen J, Gu Y, Shen W.MicroRNA-21 functions as an oncogene and promotes cell proliferation and invasion via TIMP3 in renal cancer[J]. Eur Rev Med Pharmacol Sci,2017,21(20):4566-4576.
[57] Uria JA, Ferrando AA, Velasco G, et al.Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family[J]. Cancer Res,1994,54(8):2091-2094.